Diabetic cardiomyopathy describes
heart disease in patients with diabetes who have no other cardiac conditions but have a higher risk of developing
heart failure. Specific
therapies to treat the diabetic heart are limited. A key mechanism involved in the progression of
diabetic cardiomyopathy is dysregulation of cardiac energy metabolism. The aim of this study was to determine if increasing the expression of
medium-chain acyl-coenzyme A dehydrogenase (MCAD; encoded by Acadm), a key regulator of
fatty acid oxidation, could improve the function of the diabetic heart. Male mice were administered
streptozotocin to induce diabetes, which led to diastolic dysfunction 8 weeks post-injection. Mice then received cardiac-selective adeno-associated viral vectors encoding MCAD (rAAV6:MCAD) or control AAV and were followed for 8 weeks. In the non-diabetic heart, rAAV6:MCAD increased MCAD expression (
mRNA and
protein) and increased Acadl and
Acadvl, but an increase in MCAD
enzyme activity was not detectable. rAAV6:MCAD delivery in the diabetic heart increased MCAD
mRNA expression but did not significantly increase
protein, activity, or improve diabetes-induced cardiac pathology or molecular metabolic and
lipid markers. The uptake of AAV viral vectors was reduced in the diabetic versus non-diabetic heart, which may have implications for the translation of AAV
therapies into the clinic. KEY MESSAGES: The effects of increasing MCAD in the diabetic heart are unknown. Delivery of rAAV6:MCAD increased MCAD
mRNA and
protein, but not
enzyme activity, in the non-diabetic heart. Independent of MCAD
enzyme activity, rAAV6:MCAD increased Acadl and
Acadvl in the non-diabetic heart. Increasing MCAD cardiac gene expression alone was not sufficient to protect against diabetes-induced cardiac pathology. AAV transduction efficiency was reduced in the diabetic heart, which has clinical implications.